| Literature DB >> 32555945 |
Xiaorui Cui1, Lan Li2, Lei Yu3, Huijuan Xing4, Hong Chang4, Li Zhao5, Jin Qian5, Qingwei Song6, Shiyu Zhou7, Chunbo Dong5.
Abstract
OBJECTIVES: Parkinson's disease (PD) and the parkinsonian variant of multiple system atrophy (MSA-P) are distinct neurodegenerative disorders that share similar clinical features of parkinsonism. The morphological alterations of these diseases have yet to be understood. The purpose of this study was to evaluate gray matter atrophy in PD and MSA-P using regions of interest (ROI)-based measurements and voxel-based morphometry (VBM).Entities:
Mesh:
Year: 2020 PMID: 32555945 PMCID: PMC7279630 DOI: 10.6061/clinics/2020/e1505
Source DB: PubMed Journal: Clinics (Sao Paulo) ISSN: 1807-5932 Impact factor: 2.365
Demographic characteristics of the patients with MSA-P and PD and the healthy controls.
| Patients with MSA-P (n=20) | Patients with PD (n=41) | Healthy controls (n=39) | Test statistics |
| |
|---|---|---|---|---|---|
| Male/Female | 10/10 | 17/24 | 20/19 |
| 0.65 |
| Age (years) | 66.25±8.82 | 65.22±8.82 | 62.82±6.23 |
| 0.22 |
| Education (years) | 9.50±2.76 | 8.76±4.44 | 9.36±4.29 |
| 0.73 |
| Duration of disease (months) | 41.4±22.6 | 33.71±30.39 | - |
| 0.32 |
| UPDRS (Part III) | 40.08±15.12 | 32.15±7.78 | - |
| 0.04 |
| UPDRS (Part V) | 2.98±0.91 | 2.23±0.54 | - |
| 0.01 |
Values represent the mean ± SD.
p>0.05, chi-square test, the three groups were gender matched.
p>0.05.
p>0.05, analysis of variance (ANOVA), age and education matched.
p>0.05, t-test, the disease durations of MSA-P and PD were similar.
p<0.05, t-test, the patients with MSA-P had significantly increased scale scores compared with the patients with PD. UPDRS=Unified Parkinson’s Disease Rating Scale.
Figure 1Manual ROI measurements (A, coronal; B, axial; C, sagittal) showing the putamen (red), caudate nucleus (blue) and globus pallidus (green).
Figure 2VBM analysis of the putamen, caudate nucleus and globus pallidus. In this figure, the red color represents the volumes of the bilateral putamen in controls that are larger than MSA-P (A) and the volumes of the bilateral caudate nucleus in controls that are larger than MSA-P (B); the yellow color represents the volumes of the bilateral caudate nucleus in controls that are larger than PD (C), p (uncorrected) <0.001.
Figure 3(A) VBM analysis of the gray matter comparing MSA-P and controls. The yellow-white color represents the gray matter volume (controls>MSA-P); the brown-dark color indicates the gray matter volume (MSA-P>controls). (B) VBM analysis of the gray matter comparing PD and controls. The yellow-white color represents the gray matter volume (controls>PD); the brown-dark color indicates the gray matter volume (PD>controls). (C) VBM analysis of the gray matter comparing MSA-P and PD. The yellow-white color represents the gray matter volume (PD>MSA-P); alternatively, the brown-dark color marks the gray matter volume (MSA-P>PD).
Correlation analysis between clinical parameters and gray matter atrophy.
| Diagnosis | Variables | Duration of disease | Gray matter atrophy | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Putamen (left) | Putamen (right) | Caudate nucleus (left) | Caudate nucleus (right) | Globus pallidus (left) | Globus pallidus (right) | Whole brain gray matter | |||
| MSA-P | |||||||||
| Duration of disease ( | 1.000 | -0.577 | -0.722 | -0.057 | -0.144 | -0.345 | -0.269 | -0.325 | |
| UPDRS (Part III) ( | 0.597 | -0.592 | -0.399 | 0.076 | 0.168 | 0.190 | 0.145 | 0.050 | |
| UPDRS (Part V) ( | 0.328 | -0.532 | -0.206 | 0.109 | 0.250 | 0.343 | 0.289 | 0.091 | |
| PD | |||||||||
| Duration of disease ( | 1.000 | -0.118 | -0.020 | -0.170 | -0.109 | -0.181 | -0.120 | 0.091 | |
| UPDRS (Part III) ( | 0.192 | 0.027 | 0.044 | -0.182 | -0.219 | 0.076 | 0.232 | 0.186 | |
| UPDRS (Part V) ( | 0.158 | 0.065 | 0.009 | -0.098 | -0.147 | 0.006 | 0.047 | 0.125 | |
ICV and age set as controlled variables.
r value (correlation coefficient)
p<0.05.